euNetworks Expands Its Long Haul Network to Warsaw and Bratislava, Delivering Three Routes Into Poland to Meet Bandwidth Demand
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has expanded its long haul network into Poland, delivering three new routes to Warsaw. These routes deliver around 2,977km of newly lit fibre connecting Warsaw directly with Berlin and Hamburg, with the third route via Brno, supporting traffic to Prague, Bratislava and Vienna. This expansion, which took 9 months to deliver, supports euNetworks’ customers’ demand for better diversity into the region. The system is in service, carrying multiple Terabits of customer traffic on each span that will rapidly grow.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005710/en/
euNetworks' 3 long routes to Warsaw (Graphic: Business Wire)
The new long haul routes were designed to deliver a unique triverse topology to market. Each route lands in a separate data centre in Warsaw, with scope to further expand as new data centres come into service in the region. The north route is 924km long, extends from Berlin and Hamburg and is unique in the market. Its route diversity also enables customers to bypass Berlin should they need to. The middle route is 845km long, running from euNetworks’ Berlin data centre facility into Warsaw. The south route, at 1,178km, delivers the shortest path to market between Vienna and Warsaw and enables Bratislava in Slovakia as a new point of presence for euNetworks along the way.
These routes connect into the key data centres and data centre hubs in Warsaw. This investment supports euNetworks’ customers’ bandwidth needs in this important market as well as onwards diversity and triversity to the rest of Europe. euNetworks’ long haul network now spans 17 countries, connecting 53 cities. Combined with euNetworks’ extensive metro networks in 17 cities, the long haul network enables any data centre to any data centre connectivity between all these metros on their owned and operated fibre, end-to-end.
The expansion East follows deployment of additional critical infrastructure linking the UK and the Netherlands, with euNetworks’ latest Super Highway along with subsea cable Scylla going live in September 2021.
“Warsaw is an exciting new region for data centre growth and is an important market experiencing strong bandwidth growth,” said Paula Cogan, President, euNetworks. “It’s a growing cloud region in Europe, with its geographic position making it a key connectivity hub for hyperscalers and cloud service providers. We continue to develop our network in support of our customers’ bandwidth requirements across Europe. Our expansion into Poland enables us to continue to offer a seamless and end to end data centre connectivity experience for our customers on our network with the same service delivery and support experience they have come to value.”
euNetworks’ 100g and 400G Wavelengths, 1G and 10G Ethernet, Cloud Connect and Multi Service Port products and solutions are now available in Warsaw, with plans for additional direct connection to further data centres in the region and in Warsaw to support customers’ needs in the future.
euNetworks builds and invests in its city and long haul fibre networks to connect the key data centres and data centre hubs across Europe. The company builds Super Highways on long haul routes that are critical to Europe’s future international bandwidth needs and uses low loss fibre on these routes to deliver a low cost per bit long haul solution for its customers.
About euNetworks
euNetworks is a bandwidth infrastructure company, owning and operating 17 fibre based metropolitan networks connected with a high capacity intercity backbone covering 53 cities in 17 countries across Europe. The company leads the market in data centre connectivity, directly connecting over 465 today. euNetworks is also a leading cloud connectivity provider and offers a targeted portfolio of metropolitan and long haul services including Dark Fibre, Wavelengths, and Ethernet. Wholesale, finance, content, media, mobile, data centre and enterprise customers benefit from euNetworks’ unique inventory of fibre and duct based assets that are tailored to fulfil their high bandwidth needs. For further information visit eunetworks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005710/en/
Contact information
euNetworks contact:
Hannah Britt | Senior Director, Marketing & IR | euNetworks
hannah.britt@eunetworks.com email
| +44 7717 896 446 mobile
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom